Greenwood Capital Associates LLC Purchases 1,648 Shares of Bristol-Myers Squibb (NYSE:BMY)

Greenwood Capital Associates LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 5.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 34,047 shares of the biopharmaceutical company’s stock after acquiring an additional 1,648 shares during the quarter. Greenwood Capital Associates LLC’s holdings in Bristol-Myers Squibb were worth $2,077,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $26,000. Global Wealth Strategies & Associates grew its stake in shares of Bristol-Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 275 shares during the period. Transce3nd LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $28,000. Finally, Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth approximately $28,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Price Performance

BMY stock opened at $50.13 on Thursday. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The company’s fifty day moving average price is $48.87 and its 200-day moving average price is $54.88. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market capitalization of $102.01 billion, a PE ratio of -11.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. On average, equities analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The shares were bought at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Analyst Ratings Changes

BMY has been the subject of several recent research reports. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Cantor Fitzgerald restated a “neutral” rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Jefferies Financial Group cut their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.